Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts.
Ahmad Nofal, Ayman Marei, Al-Shimaa M Ibrahim...
https://pubmed.ncbi.nlm.nih.gov/31369771Actively Recruiting
Phase 2
Age: 9Years +
All Genders
ID05291845
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts: Monotherapy Versus Combined Therapy
Led by Zagazig University · Updated on 2025-06-12
162
Participants Needed
1
Research Sites
9 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the safety and effectiveness of Candida antigen and bivalent HPV vaccine in treating common warts. The trial compares these treatments given alone or combined to see how well they clear warts and prevent recurrence. This is a Phase 2 randomized study involving patients with multiple warts. Participants are divided into three groups: one receives Candida antigen injections directly into the largest wart, another receives bivalent HPV vaccine injections, and the third group receives both treatments together. Injections are given every two weeks for up to five sessions or until the warts clear. During the study, patients will be monitored for complete, partial, or no response to treatment over three months. Researchers will also follow up for six months after recovery to check for wart recurrence. Assessments include clinical evaluation of warts and treatment safety throughout the trial.
CONDITIONS
Brief Title
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Who Can Participate
Age: 9Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, and duration, with or without distant lesions
You will not qualify if you...
- Pregnant female
- Hypersensitivity to Candida antigen or bivalent HPV vaccine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 10 weeks
Participants receive injections of Candida antigen, bivalent HPV vaccine, or both into the largest wart at 2-week intervals until complete clearance or for up to five treatment sessions.
Up to 5 visits every 2 weeks (in-person)
Follow-up
Duration - 6 months
Participants are monitored for recurrence of warts after treatment completion for up to 6 months.
Visits scheduled periodically during follow-up (in-person)
Trial Site Locations
Total: 1 location
1
Reham Essam
Zagazig, Al Sharqia, Egypt, 2543
Actively Recruiting
Loading map...
Research Team
R
Reham Essam, MD
R
Reham Essam, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Comparative efficacy of intralesional Candida antigen, intralesional bivalent human papilloma virus vaccine, and cryotherapy in the treatment of common warts.
Amany Nassar, Rania Alakad, Reham Essam...
https://pubmed.ncbi.nlm.nih.gov/34464624